Haleon half-year results 2026: interim dividend rises 9%

Haleon has announced a 9% increase in its interim dividend for the first half of 2026, taking the payment to 2.4 pence per ordinary share.

That is the main investor-relevant figure contained in the supplied announcement. Despite being titled as Haleon's 2026 half-year results, the RNS is primarily a publication notice directing shareholders to the separate full results statement.

Revenue, profit, margins, cash flow, debt and trading guidance are not disclosed in the supplied RNS text. That limits the conclusions investors can draw from this particular announcement alone.

Haleon's 2026 interim dividend at a glance

Key detail	H1 2026
Interim dividend	2.4p per ordinary share
Year-on-year increase	9%
Expected ex-dividend date for ordinary shares	13 August 2026
Record date	14 August 2026
DRIP election deadline	28 August 2026
Expected payment date	17 September 2026

The dividend increase is consistent with Haleon's policy of paying approximately one-third of the previous year's full-year dividend at the interim stage.

Investors can read the original company announcement for the formal publication notice and shareholder timetable.

What the dividend increase means

A 9% rise in the interim dividend is a clear positive for income-focused shareholders. It increases the cash payment from the equivalent period of 2025 and indicates that the board remains comfortable applying Haleon's stated distribution policy.

The company also said that, subject to market conditions and board approval, it expects to grow its ordinary dividend at least in line with adjusted earnings.

Adjusted earnings are profits calculated after removing certain items that management considers unusual or not representative of underlying performance. Investors should normally check the accompanying reconciliation to understand what has been excluded, although those details are not contained in the supplied announcement.

The wording around future dividends is encouraging, but it is not an unconditional promise. Market conditions and board approval remain explicit requirements, while future payments will depend on the company's earnings and financial position.

Important dates for Haleon shareholders

Ordinary shares are expected to trade ex-dividend on 13 August 2026. Investors buying on or after that date would not normally qualify for this payment.

The record date is 14 August 2026, with payment expected on 17 September 2026.

Holders who want to use Haleon's Dividend Reinvestment Programme, commonly shortened to DRIP, have until 28 August 2026 to make their election. A DRIP allows eligible shareholders to use cash dividends to acquire additional shares instead of receiving the payment directly as cash.

The timetable differs slightly for holders of US American Depositary Shares, or ADS. Their expected ex-dividend date is 14 August 2026.

What is missing from this RNS

The biggest issue for investors is not necessarily a negative operating development. It is the lack of detailed financial information in the supplied text.

The announcement confirms that the full half-year results statement has been published separately, but it does not reproduce the underlying numbers. The following information is therefore not disclosed here:

• Revenue and organic sales growth
• Operating profit and operating margin
• Adjusted earnings per share
• Free cash flow
• Net debt or leverage
• Performance by product category or geography
• Full-year trading guidance

Without those figures, it is not possible to assess from this notice whether Haleon's sales growth accelerated, whether margins improved or whether cash generation comfortably covered the higher dividend.

It would also be inappropriate to infer overall trading strength from the dividend increase alone. Dividends are important, but they are only one part of the investment picture.

The investor positives and risks

Positives

The immediate positive is the 9% dividend increase. Haleon is also providing a clear payment timetable and has reiterated an intention to grow ordinary dividends at least in line with adjusted earnings, subject to the stated conditions.

Its consumer health portfolio spans Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. The RNS names brands including Sensodyne, Panadol, Centrum, Advil and Voltaren.

You can find further company coverage on the Haleon PLC share page.

Risks and unanswered questions

The supplied announcement does not give investors enough information to judge the quality of Haleon's first-half performance. A higher dividend can be attractive, but shareholders still need to examine earnings, cash flow and debt to assess whether that growth is sustainable.

There is also conditional language around future dividend increases. Haleon's expectation remains subject to market conditions and board approval, so future growth is not guaranteed.

What Haleon investors should focus on next

The 2.4p interim dividend provides shareholders with a tangible 9% year-on-year increase and is the clearest takeaway from this RNS.

However, the announcement is better viewed as a results publication notice than a complete financial update. The full assessment depends on figures that are not included in the supplied text, particularly organic sales growth, margins, earnings, cash generation, debt and the company's outlook for the rest of 2026.

For now, the dividend news is positive. Whether the wider half-year performance deserves the same description cannot be determined from this announcement alone.